The novel tyrosine kinase 2 inhibitor reversed pathological vascular changes in mice kidneys and decreased fibrin and C3 deposition, suggesting a role of anti-interferon antibodies as a new therapeutic strategy to reduce vascular damage associated with APS. This evidence concerns the gene C3 and autoimmune polyendocrinopathy.